Raymond James & Associates Axogen, Inc. Transaction History

Raymond James & Associates

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$17.8 - $23.5 $188,199 - $248,465	-10,573 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$17.18 - $22.6 $181,644 - $238,949	10,573 New	10,573 $214,000
Q1 2020 Apr 21, 2020	SELL	$8.38 - $17.34 $167,474 - $346,539	-19,985 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$11.18 - $18.6 $61,881 - $102,951	5,535 Added 38.3%	19,985 $358,000
Q3 2019 Nov 07, 2019	BUY	$12.09 - $20.46 $13,552 - $22,935	1,121 Added 8.41%	14,450 $180,000
Q2 2019 Aug 06, 2019	SELL	$18.5 - $25.47 $49,210 - $67,750	-2,660 Reduced 16.64%	13,329 $264,000
Q1 2019 May 06, 2019	BUY	$14.62 - $22.13 $9,269 - $14,030	634 Added 4.13%	15,989 $337,000
Q4 2018 Feb 11, 2019	SELL	$17.09 - $38.25 $15,210 - $34,042	-890 Reduced 5.48%	15,355 $314,000
Q3 2018 Nov 14, 2018	BUY	$34.05 - $55.9 $553,142 - $908,095	16,245 New	16,245 $599,000

176

36.6M

230K

400

Ticker AXGN
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 42,283,700
Market Cap $749M
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.